Strategic Market Access
Pricing and reimbursement perspective integrated with product development
Strategic Market Access
As health systems evolve and budgets become tighter, ensuring clarity on product value proposition, future potential price levels, and reimbursement conditions is essential for patients to access medicines. ProductLife Consulting offers strategic advice on market access questions, generating insight through internal expertise, advisory boards, and market research.
We offer support from early clinical development to help clarify and stress test your product’s value proposition and make an earlier estimate of future potential price and reimbursement conditions in key countries. Along the development process, we offer support in re-assessing the strategy and helping identify the critical data to collect for market access purposes.
A service in focus: our pricing and reimbursement insight workshop service
A service in focus: our pricing and reimbursement insight workshop service
Our clients require an uncomplicated and effective approach to strategizing pricing and reimbursement outcomes, considering key competitors’ expected responses ahead of product launches.
The people supported by ProductLife Consulting
This service caters to global market access leadership or country-specific market access teams.
What sets us apart
We stand out by providing a comprehensive perspective encompassing the entire market access landscape, including its implications for adoption and patient access.
Why clients so highly value ProductLife Consulting
Mastering market access within the full lifecycle
With a global presence spanning 50 countries, our market access service is delivered by a team of life science specialists with access to expertise throughout the entire product lifecycle. This integrated approach harmonizes market access with regulatory processes, CMC development, and strategic commercial potential, delivering effective, fact-based, differentiated access strategies.
Market access due diligence - late-stage oncology compound
The challenge
Our client, a prominent European pharmaceutical company, was in the final stages of considering the acquisition of a late-stage compound (Phase III development). The compound offered two potential positioning options (second or third line), and the due diligence conducted by a generalist consultancy lacked specific insights into potential pricing variations across different countries.
Our approach
To address this, we conducted thorough desk research and gathered existing expertise to compile precise and comprehensive data on care pathways, standard of care, and current competitive pricing in the target regions. We leveraged the materials during expert interviews, engaging clinicians and payers to capture diverse perspectives. We emphasized specific points, such as using a clinical comparator (a low-priced product) and price comparisons.
Result
We delivered a comprehensive understanding of pricing-related risks and opportunities contingent on the product’s future positioning.
Market access for geographical expansion
The challenge
Our client, a pharmaceutical company initially focused on a single European country, was considering expanding its reach beyond its original market. We provided them with a tailored overview of the market access landscapes in key target countries.
Our approach
We started with current and future reimbursement and price negotiation frameworks. We then considered government entities, health technology assessment agencies, and relevant scientific societies involved in medicine assessment at the country and regional levels where applicable— moving on to procurement schemes, key organizations, and processes pertinent to the envisioned product category. In the end, we provided estimated timelines for each country, spanning from initiation to product launch.
PLG’s value in delivering results
Our client gained valuable insights into potential launch timelines, processes, and associated risks when considering expanding their products beyond their current market.